S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|NPS Pharma Reports Second-Quarter 2014 Financial Results|
|NPS Pharma Stock Trading Halted Today; FDA Advisory Committee to Review Natpara® Biologics License Application|
|FDA Posts Briefing Materials for Advisory Committee Meeting Reviewing Natpara® for Hypoparathyroidism|
|NPS Pharma Initiates Phase 2a Study of NPSP795 in Adult Patients with Autosomal Dominant Hypocalcemia (ADH)|
|NPS Pharma to Report Second Quarter 2014 Financial Results|
|FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of Hypoparathyroidism|
|NPS Pharma to Present at Upcoming Conferences|
|NPS Pharma to Present at Leerink Partners Rare Disease Roundtable|
|PARADOX Findings Published in Endocrine Practice Describe High Burden of Illness in Patients with Hypoparathyroidism|
|UPDATE: S&P 500, Nasdaq retest major support -3- (2014/8/5)|
Click above to view more mutual fund data and stats for npsp - NPS Pharmaceuticals Inc.